
|Articles|August 1, 2003
Triple Peptide Vaccine
Author(s)John Otrompke
Chicago - Data involving the first 60 patients in a phase II clinical trial of a multi-epitope peptide vaccination, as combined with other agents, showed a median survival of 21 months for immunological responders as compared to 13 months in immunologic nonresponders.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











